Live
AgilentHow Investors May Respond To Agilent Technologies (A) Upgraded Outlook And Push Into AI-Powered Diagnostics - Yahoo FinanceCellExpansion and CAR engineering of granulocyte-monocyte progenitors for cellular immunotherapyEndpoints NewsBiopharma’s LGBTQ+ leaders; Novo Nordisk hacked?; and moreScience Daily BiotechThe secret language behind animal cooperationEndpoints NewsEndpoints News History: 10 Years, Bootstrap to FTClinical OMICsImproving HSV-2 Vaccine Efficacy with Combination StrategyCellMultimodal imaging of gene expression, morphology, and activity of the same neuron10x Genomics News10x Genomics, Cleveland Clinic Team Up on Bladder Cancer Diagnostics - Zacks Investment ResearchFierceBiotechFDA warning slams Zoll Medical with multiple quality control and reporting violationsBioWorldHangzhou Innogate Pharma discovers new KAT inhibitorsBioWorldAlicorn synthesizes new AAK1 inhibitorsBioWorldChinese scientists identify new macrocyclic compounds as kinase inhibitors
10x Genomics Blog Mar 21, 2026

How ARK’s TXG Selloff and Cautious 2026 Outlook Will Impact 10x Genomics (TXG) Investors - simplywall.st

How ARK’s TXG Selloff and Cautious 2026 Outlook Will Impact 10x Genomics (TXG) Investors - simplywall.st

Body unavailable. Use the original source.